<DOC>
	<DOC>NCT01686711</DOC>
	<brief_summary>To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.</brief_summary>
	<brief_title>A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator. Those who can sign and date a written, informed consent form prior to the initiation of any study procedures. Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc. Others who are assessed to be ineligible for the study by the investigator or subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>